Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
U649782-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $350.90 | |
U649782-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $580.90 | |
U649782-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,100.90 | |
U649782-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,700.90 | |
U649782-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,500.90 |
Specifications & Purity | ≥99% |
---|---|
Biochemical and Physiological Mechanisms | UMB298 is a potent and selective CBP/P300 bromodomain inhibitor. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | UMB298 is a potent and selective CBP/P300 bromodomain inhibitor In Vitro UMB298 (0.01~10 μM; 50 days; MOLM13 and MM cells) inhibits cells growth. UMB298 (1~10 μM; 2 hours; MOLM13 cells) reduces the H3K27ac level similar to CBP30 and causes MYC depletion as a signature of CBP inhibition in acute myeloid leukemia. UMB298 (3 μM; 2hours; MOLM13 cells) down-regulates MYC expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MOLM13 and MM cells Concentration: 0.01~10 μM Incubation Time: 50 days Result: Inhibited cells growth. Western Blot AnalysisCell Line: MOLM13 cells Concentration: 1~10 μM Incubation Time: 2 hours Result: Reduced the H3K27ac level similar to CBP30 and caused MYC depletion as a signature of CBP inhibition in acute myeloid leukemia. RT-PCRCell Line: MOLM13 cells Concentration: 3 μM Incubation Time: 2 hours Result: Down-regulated MYC expression. Form:Solid IC50& Target:BRD4 5193 nM (IC 50 ) |
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-N-cyclohexyl-7-(3,5-dimethyl-1,2-oxazol-4-yl)imidazo[1,2-a]pyridin-3-amine |
---|---|
INCHI | InChI=1S/C27H31ClN4O2/c1-17-26(18(2)34-31-17)20-13-14-32-25(16-20)30-23(27(32)29-21-7-5-4-6-8-21)11-9-19-10-12-24(33-3)22(28)15-19/h10,12-16,21,29H,4-9,11H2,1-3H3 |
InChi Key | NZXSWCLCRDCHGN-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C(=NO1)C)C2=CC3=NC(=C(N3C=C2)NC4CCCCC4)CCC5=CC(=C(C=C5)OC)Cl |
Isomeric SMILES | CC1=C(C(=NO1)C)C2=CC3=NC(=C(N3C=C2)NC4CCCCC4)CCC5=CC(=C(C=C5)OC)Cl |
PubChem CID | 137409212 |
Molecular Weight | 479.01 |
Enter Lot Number to search for COA:
Solubility | DMSO : 25 mg/mL (52.19 mM; Need ultrasonic) |
---|